leisure time -WSS

leisure time

author：hotspot 2025-09-30 00:48:11 - browse：99166

Sterile capsules for injection line up in a dispensing line — politics coverage from STAT — Adobe

WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages by rewarding hospitals for business practices that ensure an adequate supply of drugs.

Drug shortages have been a persistent problem for years, and they’re worse than ever, according to a recent report by the American Society of Health-System Pharmacists. Shortages are primarily a problem for hospitals and doctors who regularly administer drugs, including oncologists who have been running out of common chemo drugs. Generic injectables account for 67% of shortages, and more than half of drugs in short supply cost less than $1 per unit, according to the Finance Committee.

Hospitals band together to negotiate drug prices by hiring group purchasing organizations. The biggest three GPOs are estimated to control about 90% of the market for drugs that hospitals buy. Finance Chair Ron Wyden (D-Ore.) said those GPOs can drive prices down so low that manufacturers stop making certain drugs or can’t afford to maintain their facilities, which then leads to manufacturing interruptions. Drugmakers also say GPOs can also be fickle, switching from one manufacturer to another over small savings, leaving drugmakers without the certainty they need to commit to making large volumes of product.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Snackable artificial intelligence, expert AI, and the pharma industry

WSS

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Trump surgeon general acknowledges mistakes during Covid

The Harvard botanist who searched for psychedelics in the Amazon

The (many) problems with a new study criticizing cancer screening

Ed Silverman on new gene therapies, biosimilars, coffee, and more

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

explore

What does generative AI mean for health care? We asked experts

Humana sues Biden admin over Medicare Advantage audit rule

United colonoscopy coverage change 'may cost lives,' doctors say

6 phony surgeries that take placebo to the extreme

Jerome Adams on the need for new antivirals for Covid

PBM reform efforts get punted in Congress

23andMe had bad news about my health. I wish a person had delivered it

How generative AI is inspiring dreams of a health data revolution

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

focus

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

NIH study of ME/CFS points to clear biological hallmarks

Stem cell treatment guidelines are released by FDA

What American doctors can learn from their Israeli counterparts

Trump surgeon general acknowledges mistakes during Covid

The (many) problems with a new study criticizing cancer screening

hotspot

leisure time

hotspot

focus